Common Contracts
7 similar null contracts by Quoin Pharmaceuticals, Ltd., Soligenix, Inc., Canoo Inc., others
ContractMeta Materials Inc. • February 21st, 2024 • Semiconductors & related devices • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Agent”), and Meta Materials Inc., a Nevada corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered securities of the Company, consisting of: (i) shares of common stock, par value $0.001 per share (“Common Stock”); (ii) Warrants to purchase Common Stock (the “Warrants”) and (iii) Pre-Funded Warrants to purchase Common Stock (the “Pre-Funded Warrants”). The Common Stock, Warrants and Pre-Funded Warrants actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The Placement Agent Securities and shares of Common Stock issuable upon the exercise of the Warra
ContractSoligenix, Inc. • January 16th, 2024 • Pharmaceutical preparations • New York
Soligenix, Inc. Attention: Christopher J. Schaber, President and Chief Executive Officer 29 Emmons Drive, Suite B-10Princeton, NJ 08540
ContractVelo3D, Inc. • December 28th, 2023 • Special industry machinery, nec • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners (the “Placement Agent”), as sole placement agent, and Velo3D, Inc., a Delaware corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, in connection with the proposed registered direct offering (the “Placement”) of securities of the Company, consisting of: (i) shares of common stock, par value $0.00001 per share (“Common Stock”), (ii) warrants to purchase Common Stock (the “Common Warrants” or the “Warrants”). The Common Stock and Warrants actually sold by the Placement Agent are referred to herein as the “Placement Agent Securities.” The Placement Agent Securities and shares of Common Stock issuable upon the exercise of the Warrants shall be offered and sold under the Company’s registration statement on Form S-3 (File No. 333-268346) (the “Registration Statement”), which was declared effective
ContractSoligenix, Inc. • April 20th, 2023 • Pharmaceutical preparations • New York
Soligenix, Inc. Attention: Christopher J. Schaber, President and Chief Executive Officer 29 Emmons Drive, Suite B-10Princeton, NJ 08540
ContractCanoo Inc. • February 6th, 2023 • Motor vehicle parts & accessories • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Agent”), and Canoo Inc., a Delaware corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered securities of the Company, consisting of: (i) shares of common stock, par value $0.0001 per share (“Common Stock”) and (ii) warrants to purchase Common Stock (the “Common Warrants”). The Common Stock and Warrants actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The Placement Agent Securities and shares of Common Stock issuable upon the exercise of the Warrants shall be offered and sold under the Company’s registration statement on Form S-3 (File No. 333-2
Quoin Pharmaceuticals Ltd. Attention: Gordon Dunn Azrieli Center, Round Tower, 30th Floor 132 Menachem Begin Blvd Tel Aviv, 6701101Quoin Pharmaceuticals, Ltd. • February 3rd, 2023 • Surgical & medical instruments & apparatus • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Agent”), and Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of not less than $10 million of registered securities of the Company, consisting of: (i) ordinary shares, no par value (the “Ordinary Shares”) represented by American Depositary Shares (the “ADSs”), with each ADS representing five thousand (5,000) Ordinary Shares, (ii) pre-funded warrants to purchase Ordinary Shares represented by ADSs (the “Pre-Funded Warrants”), and (iii) warrants to purchase ADSs (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrant
Quoin Pharmaceuticals Ltd. Attention: Gordon Dunn Azrieli Center, Round Tower, 30th Floor 132 Menachem Begin Blvd Tel Aviv, 6701101Quoin Pharmaceuticals, Ltd. • August 3rd, 2022 • Surgical & medical instruments & apparatus • New York
Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Agent”), and Quoin Pharmaceuticals Ltd., a company organized under the laws of Israel (the “Company”), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of no less than $12 million of registered securities of the Company, consisting of: (i) ordinary shares, no par value (the “Ordinary Shares”) represented by American Depositary Shares (the “ADSs”), with each ADS representing five thousand (5,000) Ordinary Shares, (ii) pre-funded warrants to purchase Ordinary Shares represented by ADSs (the “Pre-Funded Warrants”), and (iii) warrants to purchase ADSs (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants
